Navigation Links
Inappropriate Initial Antibiotic Treatment May Extend Stays for Patients with Healthcare-Associated Skin Infections
Date:10/30/2009

PHILADELPHIA, Oct. 30 /PRNewswire/ -- Patients who acquire skin and soft tissue infections (SSTIs) in a hospital or other healthcare setting may be more likely to receive inappropriate antibiotic therapy at the beginning of their treatment. As a result, they also may have significantly longer hospital stays to control the infection. Preliminary results from a new study by the Henry Ford Health System evaluated records from patients who acquired SSTIs in hospital and healthcare settings and those who acquired similar infections in the community. Results from the study, which were presented today at the 47th Annual Meeting of the Infectious Diseases Society of America (IDSA), also shed new light on baseline risk factors that are associated with inappropriate initial therapy (Abstract #053). This information may help guide clinicians in the appropriate treatment of SSTIs.

(Logo: http://www.newscom.com/cgi-bin/prnh/20091030/NY02034LOGO)

Complicated skin and skin structure infections (cSSTIs) account for almost 10 percent of all hospital admissions in the U.S.(1) According to the Centers for Disease Control and Prevention (CDC), approximately 25-30% of the U.S. population has some form of Staphylococcus aureus on their skin, and an increasing number of those individuals carry the more resistant form known as methicillin-resistant Staphylococcus aureus (MRSA).(2)(3)(4)

"Up to this point, the importance of initiating appropriate empiric* therapy has been well documented in other infections such as pneumonia, but not in skin infections," said study author Marcus Zervos, M.D. Division Head, Infectious Diseases, Director Infection Control at the Henry Ford Health System, in Detroit, MI. "These results show that a more comprehensive evaluation of hospital patient risk factors may help physicians determine the optimal initial antibiotic treatment, sparing patients unnecessary treatment and time in the hospital."

Risk Factors for Inappropriate Treatment

In the hospitalized patient population, three risk factors were identified as being associated with receiving inappropriate antibiotic treatment:

  • Healthcare-associated infection status (i.e., recent exposure within nursing homes, or medical clinics)
  • Presence of a "gram-negative" pathogen
  • Presence of a pathogen other than a Streptococcus species

Study Methods and Key Results

The study, conducted by the Henry Ford Health System with a grant from Ortho-McNeil Janssen Scientific Affairs, LLC, is an analysis of administrative and medical records of 368 patients hospitalized between late 2005 and 2008 with an admission diagnosis of a cSSTI. Patients were classified as having healthcare associated infections (HCAI) if they were: 1) recently hospitalized; 2) immunocompromised; 3) on hemodialysis; or 4) admitted from nursing home. All others were classified as having community-acquired infections (CAI). Initial empiric therapy (IET) was considered appropriate if antibiotics active against the infecting pathogen(s) were administered within 24 hours of admission.

Among patients with SSTIs whose infection was confirmed by culture ("culture-positive"), those who acquired an infection in a hospital or healthcare setting were more likely to be treated inappropriately than those who acquired an infection in a community setting (35.2% vs. 20.5%, p<0.01). Additionally, when other risk factors were adjusted, patients who received inappropriate initial therapy stayed in the hospital an average of nearly six days longer than patients who received appropriate initial therapy.

Moreover, the study showed that S. aureus was the most common pathogen in patients with both HCAI (55.6%) as well as CAI (58.2%), and the majority of these were methicillin-resistant S. aureus, commonly referred to as MRSA (73.4% in HCAI and 64.8% in CAI). MRSA represents a growing healthcare concern and has become an increasingly common cause of SSTIs, as evidenced by the prevalence of MRSA in this study.

Dr. Zervos is a principal investigator for the study and a paid consultant retained by Ortho-McNeil Janssen Scientific Affairs, LLC.

*Empiric treatment is defined as antibiotics prescribed prior to the identification of the causative pathogen(s) by culture results.

About Ortho-McNeil

Ortho-McNeil, Inc. is committed to providing innovative, high-quality prescription medicines, education and resources for patients, healthcare providers, and other members of the healthcare community in primary care, specialty and hospital settings. Based in Raritan, NJ, the company specializes in the areas of gastrointestinal and infectious diseases, pain management, women's health and urology, and has broad interest in other therapeutic categories. For more information, visit www.ortho-mcneil.com.

(1) DiNubile MJ, Lipsky BA. Complicated Infections of skin and skin structures: when the infection is more than skin deep. JAC. 2004;53

(2) Halem M., et al. 2006. Community-acquired methicillin resistant Staphylococcus aureus skin infections. Semin. Cutan. Med. Surg. 25:68-71

(3) Kluytmans-Vandenbergh M.F., et al. 2006. Community-acquired methicillin resistant Staphylococcus aureus: current perspectives. Clin. Microbiol. Infect. 12 Suppl 1:9-15

(4) Kollef M.H., and S.T. Micek. 2006. Methicillin resistant Staphylococcus aureus: a new community acquired pathogen? Curr. Opin. Infect. Dis. 19:161-168

Media Contact: Amy Firsching, 908-218-7583

SOURCE Ortho-McNeil, Inc.


'/>"/>
SOURCE Ortho-McNeil, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. New Data Showed Type 2 Diabetes Patients Experienced Greater Blood Sugar Reductions when Treated with ACTOplus met(R) (pioglitazone HCl and metformin HCl) as Initial Therapy Compared to Either Component Alone
2. Adnavance Technologies to Present Initial Data Supporting Direct Detection Molecular Diagnostic Tests at AdvaMed 2009 and BIOCOM Investor Conference
3. Omeros Prices Initial Public Offering of Common Stock at $10.00 Per Share
4. Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study
5. D-Pharm Raises NIS 85 Million in Rights Offering and Initial Public Offering (IPO) on the Tel Aviv Stock Exchange (TASE)
6. FDA Approves Tekturna HCT(R) as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent
7. AlphaVax Announces Results from Initial Testing of Its H1N1 (Swine) Influenza Vaccine
8. EntreMed Presents Initial Clinical Results for ENMD-2076
9. Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia
10. Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma
11. Applisonix Announces Breakthrough in Ultrasound Technology for Hair Removal - Average Hair Reduction of 38% Following Initial Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... BEIJING , June 24, 2016 Dehaier ... or the "Company"), which develops, markets and sells medical ... China , signed a strategic cooperation agreement with ... as "Hongyuan Supply Chain") on June 20, 2016, to ... Under the strategic cooperation agreement, Dehaier will leverage Hongyuan ...
(Date:6/24/2016)... 24, 2016 Research and Markets has ... Companion Diagnostic Tests" report to their offering. ... Diagnostics The World Market for Companion Diagnostics ... diagnostics. Market analysis in the report includes the following: ... Vitro Diagnostic Kits) by Region (N. America, EU, ROW), 2015-2020 ...
(Date:6/24/2016)... LEXINGTON, Mass. , June 24, 2016   ... specialty pharmaceutical company developing innovative inhaled drugs, announced today ... when Russell Investments reconstituted its comprehensive set ... 2016. "This is an important milestone for ... "It will increase shareholder awareness of our progress in ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
(Date:6/24/2016)... ... 2016 , ... The Pulmonary Hypertension Association (PHA) learned during ... two significant new grants to support its work to advance research and patient ... recognizing patients, medical professionals and scientists for their work in fighting pulmonary hypertension ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of ... AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to ...
(Date:6/24/2016)... ... ... BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a ... an hour by 2020 and then adjusting it yearly to increase at the same rate ... assure the wage floor does not erode again, and make future increases more predictable. , ...
Breaking Medicine News(10 mins):